122 related articles for article (PubMed ID: 30840592)
1. Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment.
Senk B; Goricar K; Kovac V; Dolzan V; Franko A
Radiol Oncol; 2019 Mar; 53(1):96-104. PubMed ID: 30840592
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.
Arrieta O; López-Macías D; Mendoza-García VO; Bacon-Fonseca L; Muñoz-Montaño W; Macedo-Pérez EO; Muñiz-Hernández S; Blake-Cerda M; Corona-Cruz JF
Cancer Chemother Pharmacol; 2014 May; 73(5):975-82. PubMed ID: 24687408
[TBL] [Abstract][Full Text] [Related]
3. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.
Erčulj N; Kovač V; Hmeljak J; Dolžan V
Ann Oncol; 2012 Apr; 23(4):961-7. PubMed ID: 21765044
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma.
Goričar K; Kovač V; Dolžan V
Pharmacogenomics; 2014 May; 15(7):941-50. PubMed ID: 24956248
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report.
Angelico G; Caltabiano R; Loreto C; Ieni A; Tuccari G; Ledda C; Rapisarda V
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495596
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
Nagata Y; Sawada R; Takashima A; Shoji H; Honma Y; Iwasa S; Amano K; Kato K; Hamaguchi T; Shimada Y; Saruta M; Boku N
Jpn J Clin Oncol; 2019 Dec; 49(11):1004-1008. PubMed ID: 31287877
[TBL] [Abstract][Full Text] [Related]
7. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
[TBL] [Abstract][Full Text] [Related]
8. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
[TBL] [Abstract][Full Text] [Related]
9. Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma.
Goričar K; Kovač V; Dolžan V
Sci Rep; 2017 Apr; 7():46537. PubMed ID: 28422153
[TBL] [Abstract][Full Text] [Related]
10. Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model.
Klebe S; Griggs K; Cheng Y; Driml J; Henderson DW; Reid G
Dis Markers; 2015; 2015():286719. PubMed ID: 25821338
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas.
Driml J; Pulford E; Moffat D; Karapetis C; Kao S; Griggs K; Henderson DW; Klebe S
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27376267
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
[TBL] [Abstract][Full Text] [Related]
14. DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
Erčulj N; Kovač V; Hmeljak J; Franko A; Dodič-Fikfak M; Dolžan V
J Thorac Oncol; 2012 Oct; 7(10):1609-17. PubMed ID: 22982660
[TBL] [Abstract][Full Text] [Related]
15. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of Long Non-Coding RNA CASC8 rs10505477 Polymorphism in Lung Cancer Susceptibility, Platinum-Based Chemotherapy Response, and Toxicity.
Hu L; Chen SH; Lv QL; Sun B; Qu Q; Qin CZ; Fan L; Guo Y; Cheng L; Zhou HH
Int J Environ Res Public Health; 2016 May; 13(6):. PubMed ID: 27249003
[TBL] [Abstract][Full Text] [Related]
17. The influence of genetic variability of DNA repair mechanisms on the risk of malignant mesothelioma.
Levpuscek K; Goricar K; Kovac V; Dolzan V; Franko A
Radiol Oncol; 2019 Mar; 53(2):206-212. PubMed ID: 30893058
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Scagliotti GV; Gaafar R; Nowak AK; Nakano T; van Meerbeeck J; Popat S; Vogelzang NJ; Grosso F; Aboelhassan R; Jakopovic M; Ceresoli GL; Taylor P; Orlandi F; Fennell DA; Novello S; Scherpereel A; Kuribayashi K; Cedres S; Sørensen JB; Pavlakis N; Reck M; Velema D; von Wangenheim U; Kim M; Barrueco J; Tsao AS
Lancet Respir Med; 2019 Jul; 7(7):569-580. PubMed ID: 31103412
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma.
Jagirdar R; Solenov EI; Hatzoglou C; Molyvdas PA; Gourgoulianis KI; Zarogiannis SG
Gene; 2013 Mar; 517(1):99-105. PubMed ID: 23313295
[TBL] [Abstract][Full Text] [Related]
20. A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.
Kim JS; Lim SY; Hwang J; Kang EJ; Choi YJ
J Korean Med Sci; 2017 Nov; 32(11):1879-1884. PubMed ID: 28960045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
